Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer

Hall, Richard D.; Gray, Jhanelle E.; Chiappori, Alberto

doi:10.1177/107327481302000105

Cited by 51 publications

(48 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31,32 Clinical trials are underway evaluating therapeutic vaccines targeting p53 in ovarian cancer, colorectal cancer, and non-small cell lung cancer. [33][34][35][36][37] Overall, p53-specific immune responses have been observed in patients, but significant reductions in tumor burdens have not been demonstrated. It has been suggested that multiple epitope vaccines, Treg elimination, and/or CTLA-4 blockade should be assessed in combination with p53 vaccines to increase their clinical efficacy.…”

Section: P53mentioning

confidence: 99%

Overexpressed oncogenic tumor-self antigens

Bright

Byrne³

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: P53mentioning

confidence: 99%

Overexpressed oncogenic tumor-self antigens

Bright

Byrne³

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…These are either monoclonal antibodies directed at the extracellular domain of the EGFR and inhibiting the binding of natural ligands to the receptor, or low molecular weight tyrosine kinase inhibitors (TKIs) that inhibit the tyrosine kinase activity of EGFR, generally by competing reversibly with ATP for the ATP binding site [26]. Targeting the EGFR with a cancer vaccine is a newly strategy currently in clinical scrutiny using the active immune deprivation of EGF ligand as important tumor growth factor (CIMAvax EGF) [27, 28]. …”

Section: Nsclc Biology and Target Antigens For Cancer Vaccinesmentioning

confidence: 99%

Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario

Rodríguez

Sánchez²

2013

CTMC

View full text Add to dashboard Cite

This review is aimed to focus on NSCLC as an emerging and promising model for active immunotherapy and the challenges for its inclusion in the current clinical scenario. Cancer vaccines for NSCLC have been focused as a therapeutic option based on the identification of a tumor hallmark and the active immunization with the related molecules that triggers cellular and/or humoral responses that consequently destroy or delay the rate of malignant progression. This therapeutic intervention in an established disease state has been aimed to impact into prolonging patient´s survival with ethically accepted quality of life. Understanding of relationship between structure and function in cancer vaccines is essential to interpret their opportunities to impact into prolonging survival and increasing quality of life in cancer patients. It is widely accepted that the failure of the cancer vaccines in the NSCLC scenario is related with its introduction in the advanced disease stages and poor performance status of the patients due to the combination of the tumor induced immunosuppression with the immune senescence. Despite first, second and emerging third line of onco-specific treatments the life expectancy for NSCLC patients diagnosed at advanced stages is surrounding the 12 months of median survival and in facts the today real circumstances are extremely demanding for the success inclusion of cancer vaccines as therapeutic choice in the clinical scenario. The kinetics of the active immunizations encompasses a sequential cascade of clinical endpoints: starting by the activation of the immune system, followed by the antitumor response and finalizing with the consequential impact on patients’ overall survival. Today this cascade of clinical endpoints is the backbone for active immunization assessment and moreover the concept of cancer vaccines, applied in the NSCLC setting, is just evolving as a complex therapeutic strategy, in which the opportunities for cancer vaccines start from the selection of the target cancer hallmark, followed by the vaccine formulation and its platforms for immune potentiating, also cover the successful insertion in the standard of care, the chronic administration beyond progression disease, the personalization based on predictors of response and the potential combination with other targeted therapies.

show abstract

“…Although significant advances have been made in the treatment of NSCLC using molecular targeted therapies such as erlotinib and crizotinib, the median OS for patients with advanced NSCLC remains low (5,6), and acquired resistance to target agents is a major clinical problem. Therefore, the development of novel therapies is needed (7).…”

Section: Introductionmentioning

confidence: 99%

Identification of a novel HLA-A*02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene

Yoshimura¹,

Tada²,

Ofuzi³

et al. 2014

Oncology Reports

View full text Add to dashboard Cite

Cancer immunotherapy is a promising new approach to cancer treatment. It has been demonstrated that a high number of tumor-specific cytotoxic T cells (CTLs) is associated with increased disease-specific survival in lung cancer patients. Identification of superior CTL epitopes from tumor antigens is essential for the development of immunotherapy for malignant tumors. The EML4-ALK fusion gene was recently identified in a subset of non-small cell lung cancers (NSCLCs). In this study we searched for HLA-A*02:01- and HLA-A*24:02-restricted epitopes derived from EML4-ALK by screening predicted EML4-ALK-derived candidate peptides for the induction of tumor-reactive CTLs. Nine EML4-ALK-derived peptides were selected by a computer algorithm based on a permissive HLA-A*02:01 or HLA-A*24:02 binding motif. One of the nine peptides induced peptide-specific CTLs from human peripheral blood mononuclear cells. We were able to generate a peptide-specific CTL clone. This CTL clone specifically recognized peptide-pulsed T2 cells and H2228 cells expressing HLA-A*02:01 and EML4-ALK that had been treated with IFN-γ 48 h prior to examination. CTL activity was inhibited by an anti-HLA-class I monoclonal antibody (W6/32), consistent with a class I-restricted mechanism of cytotoxicity. These results suggest that this peptide (RLSALESRV) is a novel HLA-A*02:01-restricted CTL epitope and that it may be a new target for antigen-specific immunotherapy against EML4-ALK-positive cancers.

show abstract

Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer

Abstract: Recent clinical trials in lung cancer demonstrate the potential of immunotherapeutics to increase overall survival in patients with lung cancer compared with the current standard of care.

Cited by 51 publications

References 45 publications

Overexpressed oncogenic tumor-self antigens

Overexpressed oncogenic tumor-self antigens

Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario

Identification of a novel HLA-A*02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene

Contact Info

Product

Resources

About